Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Payables: 2022-2025

Historic Payables for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $5.4 million.

  • Taysha Gene Therapies' Payables rose 10.26% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.1 million, marking a year-over-year decrease of 30.68%. This contributed to the annual value of $3.6 million for FY2024, which is 43.58% down from last year.
  • Taysha Gene Therapies' Payables amounted to $5.4 million in Q3 2025, which was down 29.50% from $7.7 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Payables registered a high of $24.0 million during Q2 2022, and its lowest value of $3.6 million during Q4 2024.
  • In the last 3 years, Taysha Gene Therapies' Payables had a median value of $7.5 million in 2023 and averaged $7.2 million.
  • Its Payables has fluctuated over the past 5 years, first plummeted by 59.08% in 2023, then increased by 15.31% in 2024.
  • Quarterly analysis of 4 years shows Taysha Gene Therapies' Payables stood at $10.9 million in 2022, then plummeted by 41.84% to $6.4 million in 2023, then tumbled by 43.58% to $3.6 million in 2024, then grew by 10.26% to $5.4 million in 2025.
  • Its Payables was $5.4 million in Q3 2025, compared to $7.7 million in Q2 2025 and $4.3 million in Q1 2025.